Studies have implicated tamoxifen in the pathogenesis of endometrial hyperplasia and carcinoma via activation of the mTOR pathway11–13, suggesting that targeting the mTOR pathway could mitigate tamoxifen-induced endometrial proliferation14,15. The gene discussed is MTOR; the disease is hyperplasia.